Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Two Arm, Single Dose, Crossover, Bioequivalence Study of Ayana Pharma's Doxorubicin Hydrochloride Liposome Injection (LC-101) (Investigational Product) and the US Reference Standard Doxorubicin Hydrochloride Liposome Injection (Sun Pharma), in Subjects With Ovarian Cancer.

NCT03681548 is registered in ClinicalTrials.gov with Ayana Pharma Ltd., as lead sponsor.

NCT NCT03681548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03681548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Two Arm, Single Dose, Crossover, Bioequivalence Study of Ayana Pharma's Doxorubicin Hydrochloride Liposome Injection (LC-101) (Investigational Product) and the US Reference Standard Doxorubicin Hydrochloride Liposome Injection (Sun Pharma), in Subjects With Ovarian Cancer.
Lead sponsor
Ayana Pharma Ltd.,
Phase
Phase 1
Overall status
Completed
Start date
August 29, 2018
Completion date
March 7, 2019
Enrollment
52 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer recurrent